An anonymous director reports

VECTOR SCIENCE AND THERAPEUTICS CORP. ENTERS INTO AN INVESTOR RELATIONS AGREEMENT AND GRANTS OPTIONS

Vector Science and Therapeutics Corp. has entered into an investor relations agreement with RedChip Companies Inc. through its principal, Dave Gentry, dated Aug. 24, 2026.

The IR agreement has a 12-month term, and may be renewed or otherwise amended and agreed to in writing by the parties. The company has agreed to pay RedChip $8,500 (U.S.) in advance on a monthly basis for services to be provided commencing on the effective date of the agreement. Under the terms of the IR agreement, RedChip has agreed to assist the company with certain investor-relations-related activities, including communicating with investment advisers, analysts, portfolio managers and media contacts together with perfecting investor collateral, including investor decks, and website disclosure in preparation for outreach to institutions, analysts and media outlets, all in accordance with the policies of the TSX Venture Exchange and applicable securities laws.

Pursuant to the IR agreement, the company has granted RedChip stock options to purchase up to 150,000 common shares of the company at a price of $1.80 per share. The IR options expire on Aug. 24, 2029, vesting from the grant date on a quarterly basis over the term of the IR agreement. The IR options are subject to the approval of the TSX-V.

RedChip is a U.S. investor relations firm based in Maitland, Fla. RedChip is owned by its chief executive officer, Mr. Gentry, and has no direct relationship with and is arm's length from the company, other than as disclosed in this news release. Neither RedChip nor any of its principals currently hold common shares of the company. RedChip has been granted options to purchase up to 150,000 common shares of the company pursuant to the terms of the IR agreement described above. The IR agreement and the engagement of RedChip pursuant thereto remain subject to the approval of the TSX-V.

About Vector Science and Therapeutics Corp.

Vector, headquartered in Mequon, Wis., develops novel biomechanical devices and active localized drug delivery platforms to equip clinicians with site-directed interventions where precision matters and systemic risks are unacceptable. The company's shares are listed on the TSX Venture Exchange under the symbol PAIN.

We seek Safe Harbor.